Meeting
2023 ASCO Annual Meeting
REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.
Authors
Michael Seckl
Imperial College London, London, United Kingdom
Michael Seckl , Ehsan Ghorani , Matteo Quartagno , Fiona Helen Blackhall , Duncan C. Gilbert , Mary E.R. O'Brien , Christian H.H Ottensmeier , Elena Pizzo , James F. Spicer , Alex Williams , Philip David Badman , Mahesh K. B. Parmar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05085028
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9145)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9145
Abstract #
TPS9145
Poster Bd #
130a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2024 ASCO Annual Meeting
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.
First Author: Melissa Lynne Johnson
Poster
2024 ASCO Annual Meeting
Randomized phase III study comparing suspension or continuation of PD-1 pathway blockade for patients with advanced non-small-cell lung cancer (SAVE study: JCOG1701).
First Author: Yasushi Goto
First Author: Jeddeo Paul